Batavia Bioservices, a Netherlands-based service provider aiding the development of complex biological medicines, has launched a U.S. facility in Woburn, Mass.
“We have been growing more than 400% in the past two years in the Netherlands and to keep up with customer demand we have decided to launch a facility in the Boston area,” said Menzo Havenga, president and CEO of Batavia.
Christopher Yallop, COO of Batavia, added, “We have chosen the Greater Boston Area due to its importance as a biotech cluster. Positioning ourselves here allows us to be close to our customers, which we deem extremely important in delivering on time and on budget.”
The 5,500 sq. foot facility is located at Cummings Properties’ TradeCenter and contains multiple BSL-2 laboratories dedicated to specific tasks including molecular biology, mammalian cell line generation, protein production, protein purification and assay development. The company has already hired six employees for the new facility, with plans to hire four more by the end of this year.
“We are excited to welcome Batavia Bioservices to the Massachusetts Life Sciences community,” said Susan Windham-Bannister, Ph.D., president and CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick’s 10-year, $1 billion Life Sciences Initiative. “Batavia provides important services to the life sciences industry sectors, and the company's presence in Massachusetts will contribute to our economy, as well as strengthen our life sciences ecosystem. I am confident that the team at Batavia will find all of the resources and partners they need to thrive in Massachusetts.”